Status:

TERMINATED

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Lead Sponsor:

Y-mAbs Therapeutics

Conditions:

Neuroblastoma

CNS Metastases

Eligibility:

All Genders

Up to 18 years

Phase:

PHASE2

PHASE3

Brief Summary

Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal anti...

Detailed Description

One 131I-omburtamab treatment cycle takes 4 weeks and includes a treatment dose, and an observation period and post-treatment evaluations. One 131I-omburtamab treatment cycle for Japan only takes 5 w...

Eligibility Criteria

Inclusion

  • Patients must have a histologically confirmed diagnosis of neuroblastoma with relapse in the central nervous system or in the meninges (leptomeningeal).
  • Patients must be between the ages of birth and 18 years at the time of screening.
  • Patients must have a life expectancy of at least 3 months.

Exclusion

  • Patients with primary neuroblastoma in central nervous system.
  • Patients must not have an uncontrolled life-threatening infection.
  • Patients must not have received cranial or spinal irradiation less than 3 weeks prior to first dose of 131I-omburtamab in this trial.
  • Patients must not have received systemic chemotherapy (corticosteroids not included) less than 3 weeks prior to enrollment in this trial.
  • Patients must not have severe major non-hematologic organ toxicity; specifically, any renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity must fall below Grade 3 prior to enrollment in this trial. Patients with stable neurological deficits (due to brain tumor) are not excluded. Patients with Grade 3 or lower hearing loss are not excluded.

Key Trial Info

Start Date :

December 11 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 2 2023

Estimated Enrollment :

52 Patients enrolled

Trial Details

Trial ID

NCT03275402

Start Date

December 11 2018

End Date

June 2 2023

Last Update

February 13 2024

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Childrens Hospital Los Angeles

Los Angeles, California, United States, 90027

2

Riley Hospital for Children

Indianapolis, Indiana, United States, 46202

3

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

4

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205